Validation, revision and extension of the follicular lymphoma international prognostic index (FLIPI) in a population-based setting

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1697-1702

  van de Schans, S A M ^a   Steyerberg, E W ^b   Nijziel, M R ^c   Creemers, G J ^d   Janssen Heijnen, M L ^a   van Spronsen, D J ^e  

^a Eindhoven Cancer Registry   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Comorbidity; FLIPI; Population based; Revision; Validation

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISCRIMINANT VALIDITY; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; HIGH RISK POPULATION; HUMAN; INSTRUMENT VALIDATION; INTERNAL VALIDITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; VALIDATION STUDY;

AGE FACTORS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LYMPH NODES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; NETHERLANDS; POPULATION GROUPS; PROGNOSIS; REGISTRIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 70349651003     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp053     Document Type: Article

References (26)

1. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
2. van Dijk MR, Steyerberg EW, Stenning SP, Habbema JD. Survival estimates of a prognostic classification depended more on year of treatment than on imputation of missing values. J Clin Epidemiol 2006; 59: 246-253.
3. Clark TG, Altman DG. Developing a prognostic model in the presence of missing data: An ovarian cancer case study. J Clin Epidemiol 2003; 56: 28-37.
4. Arcaini L, Colombo N, Passamonti F et al. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res 2006; 30: 277-282.
5. Buske C, Hoster E, Dreyling M et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
6. Montoto S, Lopez-Guillermo A, Altes A et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004; 15: 1484-1489.
7. Plancarte F, Lopez-Guillermo A, Arenillas L et al. Follicular lymphoma in early stages: High risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 2006; 76: 58-63.
8. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515-524.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
10. de Rijke JM, Schouten LJ, Schouten HC et al. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol 1996; 7: 677-685.
11. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999; 78: 315-319.
12. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: Prognostic impact independent of International Prognostic Index. Br J Haematol 2005; 129: 597-606.
13. Coebergh JWW, Janssen-Heijnen MLG, Louwman WJ, Voogd AC. Cancer Incidence, Care and Survival in the SOUTH of The Netherlands, 1955-1999: A Report of the Eindhoven Cancer Registry with Cross Border Implications. Eindhoven, The Netherlands: Comprehensive Cancer Centre South (IKZ) 2001.
14. Kieszak SM, Flanders WD, Kosinski AS et al. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol 1999; 52: 137-142.
15. Janssen-Heijnen ML, Houterman S, Lemmens VE et al. Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approach. Crit Rev Oncol Hematol 2005; 55: 231-240.
16. van de Schans SA, Janssen-Heijnen ML, Biesma B et al. COPD in cancer patients: Higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient. Eur J Cancer 2007; 43: 2194-2202.
17. van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival models. Stat Med 2000; 19: 3401-3415.
18. Harell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer 2001.
19. Luminari S, Federico M. Prognosis of follicular lymphomas. Hematol Oncol 2006; 24: 64-72.
20. Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783-789.
21. Steward WP, Crowther D, McWilliam LJ et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988; 61: 441-447.
22. Decaudin D, Lepage E, Brousse N et al. Low-grade stage III-IV follicular lymphoma: Multivariate analysis of prognostic factors in 484 patients-a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999; 17: 2499-2505.
23. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 2006; 25: 127-141.
24. Maartense E, Kluin-Nelemans HC, le Cessie S et al. Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age. Cancer 2000; 89: 2667-2676.
25. Perea G, Altes A, Montoto S et al. Prognostic indexes in follicular lymphoma: A comparison of different prognostic systems. Ann Oncol 2005; 16: 1508-1513.
26. Federico M, Guglielmi C, Luminari S et al. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. Haematologica 2007; 92: 1482-1488.